Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer

Pharmacogenetics and Genomics

Volumn 21, Issue 11, 2011, Pages 760-768

  Wong, Nan Soon ^a   Seah, Elaine Z H ^b   Wang, Ling Zhi ^c   Yeo, Wee Lee ^b   Yap, Hui Ling ^c   Chuah, Benjamin ^b   Lim, Yi Wan ^b   Ang, Peter C S ^d   Tai, Bee Choo ^e   Lim, Robert ^b   Goh, Boon Cher ^b,c   Lee, Soo Chin ^b,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d GLENEAGLES HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

breast cancer; pharmacogenetics; UGT2B17; UGT2B17 2; vorinostat

Indexed keywords

EXEMESTANE; IBUPROFEN; VORINOSTAT;

ADULT; ALLELE; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; ASIA; ASIAN; BLEEDING; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; FEVER; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERTRANSAMINASEMIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING; WILD TYPE;

EID: 80055016793     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834a8639     Document Type: Article

References (43)

1. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-463.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692.
3. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36.
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-428.
5. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400.
6. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003; 3:344-351.
7. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-299.
8. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13:477-483.
9. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931.
10. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21:427-436.
11. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95:3003-3007.
12. Richon VM,Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93:5705-5708.
13. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389:349-352.
14. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000; 6:849-866.
15. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 1999; 19:4999-5005.
16. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61:8492-8497.
17. FDA. Zolinza, Clinical pharmacology and pharmaceutics review 2006 http:// www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction = Search.Label-ApprovalHistory#apphist; 2006.
18. Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69:2981-2989.
19. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study. Clin Cancer Res 2008; 14:7138-7142.
20. Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, et al. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics 2010; 20:638-641.
21. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, Ohlsson C, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91:687-693.
22. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15:1473-1478.
23. Xue Y, Sun D, Daly A, Yang F, Zhou X, Zhao M, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet 2008; 83:337-346.
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
25. Zhao Z. Early stopping clinical trials of binomial response with an exact group sequential method. Stat Med 2007; 26:1724-1729.
26. Wilson W 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, Detwiler DA, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84:707-714.
27. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265:17174-17179.
28. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:56-62.
29. Sun D, Chen G, Dellinger RW, Sharma AK, Lazarus P. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics 2010; 20:575-585.
30. Turgeon D, Carrier JS, Chouinard S, Belanger A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos 2003; 31:670-676.
31. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006; 5:1967-1974.
32. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatiniβ-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101:3236-3239.
33. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004; 92:223-237.
34. Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008; 87:133-141.
35. Munster PN, Lacevic M, Thomas S, Christian C, Ismail-Khan R, Melisko M, Rugo H. Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. J Clin Oncol 2009; 27:15s (Suppl; abstr 1075).
36. Garcia-Manero G,Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J,WierdaWG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat [suberoylanilide hydroxamic acid (SAHA)] in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111:1060-1066.
37. Lindemann RK, Newbold A,Whitecross KF, Cluse LA, Frew AJ, Ellis L, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104:8071-8076.
38. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, et al. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 2007; 104: 17777-17782.
39. Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008; 112: 2896-2905.
40. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68:3785-3794.
41. Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009; 280:177-183.
42. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14: 1669-1677.
43. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98:604-610.